在急性缺血性中风中,在血栓缓解疗法后18小时开始服用低剂量阿司匹林
Aubrey Murphy1, Leslie A Hamilton1,2, Kalene Farley2
1Department of Pharmacy, University of Tennessee Medical Center, Knoxville.
The neurologist
|June 7, 2024
概括
在急性缺血性中风治疗后24小时内服用低剂量阿司匹林 (81毫克) 并没有增加出血. 早期使用阿司匹林可能有助于预防二次栓塞,而不会恶化临床结果.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血栓溶解药物治疗是急性缺血性中风的关键治疗方法.
- 血栓溶解后开始抗血小板治疗的最佳时间,例如低剂量阿司匹林 (81毫克),仍在调查中.
- 早期服用阿司匹林可能会降低二次栓塞的风险.
研究的目的:
- 为了评估低剂量阿司匹林 (81毫克) 在急性缺血性中风的静脉栓塞治疗后24小时内给予的安全性和临床结果.
- 评估早期阿司匹林给药对内出血和其他次要结果的影响.
主要方法:
- 一项回顾性队列研究,涉及130名患者,他们接受了急性缺血性中风的阿尔泰或基治疗.
- 根据阿司匹林的服用时间分组患者: ≤24小时 (n=50) 或>24小时 (n=80) 血栓溶解后.
- 评估的结果包括内出血,中风评分,停留时间,功能结果,再入院和死亡率.
主要成果:
- 在24小时以上服用阿司匹林的组中发生了一次新的内出血;在两组之间没有观察到出血事件的显著差异.
- 在二次结果中没有发现统计学意义上的差异,尽管≤24小时组的死亡率更高,住院时间更短.
- 在≤24小时组中,阿司匹林的平均服用时间为21.1小时 (SD±6.2),在≥24小时组中为34小时 (SD±8.2).
结论:
- 在急性缺血性中风治疗后24小时内服用低剂量阿司匹林 (81毫克) 是安全的,并且不会增加出血事件.
- 较早的阿司匹林启动显示了预防二次栓塞的潜力,没有不良的临床结果.
- 需要进一步的随机对照试验来证实这些发现.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
519
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
519
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:16Clot Retraction and Fibrinolysis
5.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.5K